Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Rationale Drugs that reduce relapse in alcoholics are thought to inhibit either positive reinforcement for drinking (e.g. naltrexone) or negative reinforcement (e.g. acamprosate), and may reduce the impact of conditioned stimuli associated with previous alcohol use. We have developed a model for such conditioning by repeatedly pairing ethanol administration with plus-maze exposure. Substitution of saline for ethanol greatly increased stretched-attend postures and time in the central square, conditioned to the environment. Objective To test the hypothesis that if this behaviour indicates a negative affective state caused by the expectation of ethanol, it should be inhibited by drugs that reduce negative, but not positive, reinforcement. Methods The effects of naltrexone and acamprosate on alcohol-conditioned abstinence behaviour were compared. Results Acute administration of either drug alone produced no significant effects on plus-maze behaviour in naive mice. Naltrexone had no significant effect on the alcohol-conditioned abstinence behaviour, but acamprosate reduced the incidence of stretched-attend postures. Conclusions The experiments replicated previous findings for alcohol/environment conditioned behaviour, and demonstrated, as predicted, that this was decreased by acamprosate but not by naltrexone. Effects of acamprosate on conditioned negative reinforcement may be the cause of this effect, but more work is required to establish the usefulness of this model in evaluati…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acamprosate was developed from animal models of dependence-induced drinking (Le Magnen et al., 1987) and also blocked hyperkatifeia that was associated with alcohol withdrawal in rodent models (Cole et al., 2000).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Cole et al., 2000
Citations
Cites
The use of a plus-maze to measure anxiety in the mouse
Lister, R. (1987) · Psychopharmacology · doi:10.1007/bf00177912 · Cited by 2,609
The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain
Solomon, R. L. (1980) · American Psychologist · doi:10.1037/0003-066x.35.8.691 · Cited by 1,194 · cited 2×
“In this hypothesis, relapse is presumed to occur commonly in response to cues (external or internal) previously associated with alcohol drinking ( Solomon 1980 ).”
BackgroundRodgers, R. J., & Johnson, N. J. T. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00138-m · Cited by 791 · cited 1×
“Effects on conditioned behaviour by this mechanism are entirely consistent with the role of NMDA receptors in conditioned associative learning (see Ono et al. 1995 ), including conditioned place preference to opiate drugs (Tzschentke and Schmidt 1995).”
BackgroundAnxiogenic stimuli in the elevated plus-maze
Treit, D., Menard, J., & Royan, C. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90492-c · Cited by 628 · cited 1×
“As previous work has shown the importance of thigmotactic cues provided by the walls of the maze ( Treit et al. 1993 ), head-dipping, rears and stretched-attend postures were differentiated as “unprotected” (occurring on/from the open arms) or “protected” (occurring on/from the relative security of the central platfor…”
BackgroundRelapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass, H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080023006 · Cited by 479 · cited 1×
“…two pharmacotherapies have performed successfully in clinical trials, and these drugs offer considerable hope for a reduced incidence of relapse in the future: they are the opiate antagonist, naltrexone (Volpicelli et al. 1992), and the homotaurine derivative, acamprosate (Sass et al. 1996).”
BackgroundAnti-craving compounds for ethanol: new pharmacological tools to study addictive processes
Spanagel, R., & Zieglgänsberger, W. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)89800-8 · Cited by 291 · cited 4×
“For this reason, it has been proposed that inhibitory effects of the drugs against alcohol reinforcement extend to conditioned reinforcement for drinking behaviour (Littleton 1995; Spanagel and Ziegelgansberger 1997).”
BackgroundInfluentialAcamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat
Spanagel, R., Hölter, S. M., Allingham, K., Landgraf, R., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00174-4 · Cited by 274 · cited 5×
“Both drugs significantly reduce the incidence of relapse drinking during abstinence, and seem also to reduce the severity of relapse if it occurs ( Spanagel and Ziegelgansberger 1997 ).”
BackgroundResultInfluentialAcamprosate in alcohol dependence: how does it work?
LITTLETON, J. (1995) · Addiction · doi:10.1111/j.1360-0443.1995.tb01088.x · Cited by 178 · cited 4×
“For this reason, it has been proposed that inhibitory effects of the drugs against alcohol reinforcement extend to conditioned reinforcement for drinking behaviour (Littleton 1995; Spanagel and Ziegelgansberger 1997).”
BackgroundInfluentialSelf-citationZeise, M. L., Kasparov, S., Capogna, M., & Zieglgänsberger, W. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90682-8 · Cited by 175 · cited 1×
“The mechanism for this effect of acamprosate is unknown, but recently reported modulatory effects on NMDA receptors are consistent with the effect (Zeise et al. 1993; Al Qatari et al. 1998; Berton et al. 1998; Naassila et al. 1998).”
BackgroundCole, J. C., & Rodgers, R. J. (1994) · Psychopharmacology · doi:10.1007/bf02244851 · Cited by 171
Self-citation
Cited by
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“Acamprosate was developed from animal models of dependence-induced drinking (Le Magnen et al., 1987) and also blocked hyperkatifeia that was associated with alcohol withdrawal in rodent models (Cole et al., 2000).”
BackgroundGianoulakis, C. (2001) · PubMed · Cited by 236
Neuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
Self-citationVassiljev, V. (2004) · DSpace repository (University of Tartu) · Cited by 176
The clinical pharmacology of acamprosate
Kalk, N. J., & Lingford-Hughes, A. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12070 · Cited by 147
Stinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300487 · Cited by 139
“Acamprosate also has some effects in preventing aversive effects associated with ethanol withdrawal (Spanagel et al, 1996b; Cole et al, 2000).”
BackgroundBachteler, D., Economidou, D., Danysz, W., Ciccocioppo, R., & Spanagel, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300657 · Cited by 136
“Importantly, in several other studies it has been shown that acamprosate reduces ethanol-conditioned effects that are known to be under the control of the dopaminergic system (Cole et al, 2000; Quertemont et al, 2002; McGeehan and Olive, 2003).”
BackgroundPharmacological validation of a new animal model of alcoholism
Spanagel, R., & Hölter, S. M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070068 · Cited by 132
“alcohol withdrawal has been presented (Cole et al., 2000) and acamprosate reduced the conditioned response to alcohol withdrawal supporting our Pharmacological validation of a new animal model of alcoholism 675”
BackgroundMethodLittleton, J., & Zieglgänsberger, W. (2003) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2003.tb00492.x · Cited by 110
Self-citationAcamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
Mason, B., & Heyser, C. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966641 · Cited by 103
“Acamprosate has also been shown to attenuate ethanol withdrawal anxiety-like behavior in the plus-maze test [70,71] and to attenuate handling induced convulsions during ethanol withdrawal [72].”
BackgroundHeyser, C. J., Moc, K., & Koob, G. F. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300175 · Cited by 113
“Acamprosate also has been reported to attenuate some of the behavioral and neurochemical events associated with ethanol withdrawal (Dahchour and de Witte, 1999; Putzke et al, 1996; Cole et al, 2000).”
BackgroundInteractions between taurine and ethanol in the central nervous system.
Olive, M. F. (2002) · Amino Acids · doi:10.1007/s00726-002-0203-1 · Cited by 113
Harris, B. R., Gibson, D. A., Prendergast, M., Blanchard, J. A., Holley, R. C., Hart, S. R., Scotland, R. L., Foster, T. C., Pedigo, N. W., & Littleton, J. M. (2003) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000093601.33119.e3 · Cited by 98
Self-citationEffects of Acamprosate on Ethanol-Seeking and Self-Administration in the Rat
Czachowski, C. L., Legg, B. H., & Samson, H. H. (2001) · Alcoholism Clinical and Experimental Research · doi:10.1097/00000374-200103000-00005 · Cited by 89
New Pharmacological Treatment Strategies for Relapse Prevention
Spanagel, R., & Vengeliene, V. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_205 · Cited by 86
Smoking kills (alcoholics)! shouldn't we do something about it?
Littleton, J., Barron, S., Prendergast, M., & Nixon, S. J. (2007) · Alcohol and Alcoholism · doi:10.1093/alcalc/agm019 · Cited by 85
“…is believed to act as an indirect inhibitor of NMDAR function (Littleton and Zieglgansberger, 2003; De Witte et al., 2005) and is suggested to suppress both protracted alcohol withdrawal, and alcohol-conditioned responses that precipitate relapse (Cole et al., 2000; McGeehan and Olive 2003).”
Self-citationCowen, M. S., Adams, C., Kraehenbuehl, T., Vengeliene, V., & Lawrence, A. (2005) · Addiction Biology · doi:10.1080/13556210500223132 · Cited by 85
“…indicated that acamprosate can indeed prevent the conditioned behavioural responses to environmental stimuli associated previously with ethanol (Cole et al., 2000; Quertemont et al., 2002) as well as the reinstatement of alcohol-seeking behaviour by stimuli conditioned secondarily to ethanol…”
BackgroundMcgeehan, A. J., & Olive, M. F. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705059 · Cited by 79
“Our data are in agreement with several recent studies indicating that acamprosate can also reduce some of the environmentally conditioned motor e ects of ethanol (Cole et al., 2000; Quertemont et al., 2002).”
ResultEffect of acamprosate and naltrexone, alone or in combination, on ethanol consumption
Stromberg, M. F., Mackler, S. A., Volpicelli, J. R., & O’Brien, C. P. (2001) · Alcohol · doi:10.1016/s0741-8329(00)00137-3 · Cited by 81
Acute Effects of Acamprosate and MPEP on Ethanol Drinking‐in‐the‐Dark in Male C57BL/6J Mice
Gupta, T., Syed, Y. M., Revis, A. A., Miller, S. A., Martinez, M., Cohn, K. A., Demeyer, M. R., Patel, K. Y., Brzezinska, W. J., & Rhodes, J. S. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00787.x · Cited by 76
“…in animal models of alcohol withdrawal (Schroeder et al., 2005; Spanagel et al., 1996), relapse (Bachteler et al., 2005; Backstrom et al., 2004; Cole et al., 2000; Quertemont et al., 2002) and reinforcement (Besheer et al., 2008), and new data in mice support the hypothesis that part of the…”
BackgroundInfluentialHammarberg, A., Jayaram‐Lindström, N., Beck, O., Franck, J., & Reid, M. S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1515-6 · Cited by 70
“Preclinical studies have demonstrated acamprosate’s effects in a number of different behavioral paradigms such as a decrease in self-administration (e.g., Spanagel et al. 1996); a decrease in operant selfadministration behavior (e.g., Holter et al. 1997); a reduction of cue-induced reinstatement of alcohol-seeking beh…”
BackgroundKotlinska, J. H., & Bochenski, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.026 · Cited by 58
Jacquot, C., Croft, A. P., Prendergast, M. A., Mulholland, P., Shaw, S. G., & Little, H. J. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00799.x · Cited by 49
Self-citationCan craving be modeled in animals? The relapse prevention perspective
Littleton, J. (2000) · Addiction · doi:10.1046/j.1360-0443.95.8s2.18.x · Cited by 45
Self-citationThe neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence
Mason, B. J., & Heyser, C. J. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903512943 · Cited by 51
“Acamprosate also has been reported to attenuate some of the behavioral and neurochemical events associated with ethanol withdrawal [70,71].”
BackgroundPharmacology of Acamprosate: An Overview
Zornoza, T., Cano, M. J., Polache, A., & Granero, L. M. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00260.x · Cited by 51
“This model was used in 2000 (14) to describe the effects of acamprosate and naltrexone on the behavior that best characterizes this conditioned abstinence model, namely the increase in stretched-attend postures.”
MethodAdvances in Medications and Tailoring Treatment for Alcohol Use Disorder
Seneviratne, C., & Johnson, B. A. (2015) · Alcohol research · doi:10.35946/arcr.v37.1.02 · Cited by 49
“1998) and by causing a negative affective state during alcohol withdrawal (Cole et al. 2000).”
BackgroundResultRipley, T. L., & Stephens, D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01406.x · Cited by 50
“, 2005), by attenuating conditioned opponent processes associated with exposure to alcohol related cues (Littleton, 1995; Cole et al., 2000).”
BackgroundFarook, J. M., Morrell, D. J., Lewis, B., Littleton, J. M., & Barron, S. (2007) · Alcohol and Alcoholism · doi:10.1093/alcalc/agm047 · Cited by 48
Self-citationScheit, D. J. F., Ribeiro, A. F., Pigatto, G., Goeldner, F. O., & de Lacerda, R. B. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0416-z · Cited by 45
“The authors suggested that this model could be useful in the study of drugs effective in the control of relapse to alcohol use (Cole et al., 2000).”
BackgroundAlcohol Withdrawal and Conditioning
Little, H. J., Stephens, D., Ripley, T. L., Borlikova, G. G., Duka, T., Schubert, M., Albrecht, D., Becker, H. C., Lopez, M. F., Weiss, F., et al. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000156737.56425.e3 · Cited by 43
Self-citationAlcohol Effects During Acamprosate Treatment: A Dose‐Response Study in Humans
Brasser, S. M., McCaul, M. E., & Houtsmuller, E. J. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000130802.07692.29 · Cited by 43
de Abreu, M. S., Giacomini, A. C. V. V., Demin, K. A., Galstyan, D. S., Zabegalov, K. N., Kolesnikova, T. O., Amstislavskaya, T. G., Strekalova, T. V., Petersen, E. V., & Kalueff, A. V. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173205 · Cited by 37
Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes
Reilly, M. T., Lobo, I. A., McCracken, L. M., Borghese, C. M., Gong, D., Horishita, T., & Harris, R. A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00569.x · Cited by 37
“For example, acamprosate inhibits the development of conditioned place preference to alcohol (McGeehan and Olive, 2003) and conditioned abstinence behavior from repeated alcohol exposure, a measure of alcohol negative reinforcement (Cole et al., 2000).”
BackgroundAdolescence, glucocorticoids and alcohol
Prendergast, M., & Little, H. J. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.008 · Cited by 34
Self-citationFarook, J. M., Krazem, A., Lewis, B., Morrell, D. J., Littleton, J. M., & Barron, S. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.05.020 · Cited by 28
Self-citationPokk, P., Sepp, E., Vassiljev, V., & Väli, M. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.3.193 · Cited by 26
“In accordance with numerous data in the literature, chronic ethanol administration induced an anxiolytic, whereas ethanol withdrawal induced an anxiogenic, effect in the plus-maze test (Onaivi et al., 1989; File et al., 1993; Cole et al., 2000).”
The development of acamprosate as a treatment against alcohol relapse
Kufahl, P. R., Watterson, L. R., & Olive, M. F. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.960840 · Cited by 21
Polyamine Modulation of NMDARs as a Mechanism to Reduce Effects of Alcohol Dependence
Barron, S., Lewis, B., Wellmann, K. A., Carter, M., Farook, J. M., Ring, J., Rogers, D. T., Holley, R. C., Crooks, P. A., & Littleton, J. M. (2012) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912800673128 · Cited by 20
“Acamprosate reduced this response at 200 mg/kg IP [195], and was used as the positive control.”
BackgroundMethodSelf-citationChester, J. A., Grahame, N. J., Li, T., Lumeng, L., & Froehlich, J. C. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200111000-00015 · Cited by 20
“No adverse effects of acamprosate have been found in mice treated with this Ž .dose Cole et al., 2000 , and it is well below the i.p. dose that produces acute toxicity in mice Ž .1500 mg kg; Groupe Lipha .”
BackgroundA behavioral and pharmacological characterization of palatable diet alternation in mice
Moore, C. F., Schlain, G. S., Mancino, S., Sabino, V., & Cottone, P. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.10.013 · Cited by 16
“9%) (Cole et al., 2000) and administered intraperitoneally (0, 1 mg/kg, 10 mg/kg, 30 min pretreatment).”
Kotlinska, J. H., Łopatyńska-Mazurek, M., Gaweł, K., Gabka, P., Jenda, M., Kruk-Słomka, M., Marszałek‐Grabska, M., Danilczuk, Z., Kędzierska, E., Talarek, S., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172512 · Cited by 14
Gibuła‐Tarłowska, E., Marszałek‐Grabska, M., Witkowska, E., Izdebski, J., & Kotlinska, J. H. (2015) · Alcohol · doi:10.1016/j.alcohol.2015.01.007 · Cited by 13
Kotlinska, J. H., Pachuta, A., Bochenski, M., & Silberring, J. (2009) · Peptides · doi:10.1016/j.peptides.2009.02.002 · Cited by 11
Recent advances in the treatment of alcoholism
Pettinati, H. M., & Rabinowitz, A. R. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.011 · Cited by 11
Donoghue, K., Hermann, L. L., Brobbin, E., & Drummond, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263350 · Cited by 9
Donoghue, K., Boniface, S., Brobbin, E., Byford, S., Coleman, R., Coulton, S., Day, E., Dhital, R., Farid, A., Hermann, L. L., et al. (2023) · Health Technology Assessment · doi:10.3310/dqkl6124 · Cited by 11
Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic
Little, H. J., McKinzie, D. L., Setnik, B., Shram, M. J., & Sellers, E. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00025-4 · Cited by 9
Self-citationQuintrell, E., Wyrwoll, C. S., Rosenow, T., Larcombe, A. N., & Kelty, E. A. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.114037 · Cited by 8
New Developments in Addiction Treatment
O’Brien, C. P., Koob, G. F., Mee-Lee, D., & Rosenthal, R. N. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1119 · Cited by 8
“This medication has been shown to reduce alcohol intake(32) and alcohol craving,(33) increase alcohol abstinence, and alleviate anxiety associated with the negative reinforcement of alcohol dependence.(36) Studies(37,38) have indicated that acamprosate is effective in treating patients who have severe, chronic alcohol…”
Backgroundda Cruz, J. N., de Lima, D. D., Magro, D. D. D., & da Cruz, J. G. P. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 8
Jansone, B., Rumaks, J., Dzirkale, Z., Pupure, J., Svirskis, Š., Muceniece, R., & Kluša, V. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.12.008 · Cited by 5
“A control group was given saline i.p. for 10 days (adapted from Cole et al., 2000).”
Molecular and behavioral effects of Acamprosate in male rats with sodium salicylate-induced tinnitus
Farrahizadeh, M., Mahmoudian, S., Akbarnejad, Z., Joghataei, M. T., Farhadi, M. R., & Shahbazi, A. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115370 · Cited by 3
Alshehri, F. S. (2023) · Medicina · doi:10.3390/medicina59061101 · Cited by 3
“Research on rats suggested that it reduced the increased ethanol consumption associated with abstinence from ethanol [52].”
BackgroundÕkva, K., Lang, A., Pokk, P., Väli, M. M., & Nevalainen, T. O. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.008 · Cited by 3
Chronic Simvastatin Treatments Attenuate Ethanol Withdrawal Syndrome in Rats
Carrocini, M. M. S., Caxambú, A. L. R. L., Kelle, N. S., de Lima, D. D., da Cruz, J. N., Magro, D. D. D., & da Cruz, J. G. P. (2012) · American Journal of Medicine and Medical Sciences · doi:10.5923/j.ajmms.20120202.06 · Cited by 2
“In accordance with numerous data in the literature ethanol withdrawal induces an anxiogenic effect in the elevated plus-maze[16,17] and decrease in locomotion measured in the open-field[18].”
Background"Utilização do acamprosato no tratamento de dependentes de álcool"
Baltieri, D. A. (2002) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2002.tde-05092006-232745 · Cited by 2
TAURINE AND ETHANOL IN CENTRAL NERVOUS SYSTEM: POSSIBLITY MECHANISMS INTERACTIONS
Шейбак, В. М. (2006) · Health and Ecology Issues · doi:10.51523/2708-6011.2006-3-2-20 · Cited by 1
Mechanism of Action of Acamprosate Focusing on the Glutamatergic System
Zieglgänsberger, W., Rammes, G., Spanagel, R., Danysz, W., & Parsons, C. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-306-4_27 · Cited by 1
Albrecht, J., Zielińska, M., Allen, J., Soldin, O., & Aschner, M. (2005) · Elsevier eBooks · doi:10.1016/b978-012564370-2/50068-4
Lewis, J. (2011) · UKnowledge (University of Kentucky)
Effects of litter and cage furniture on mouse anxiety-like behaviour
Õkva, K. (2012) · Helda - University of Helsinki Institutional Repository
Robinson, S. L. (2015) · WakeSpace Scholarship (Wake Forest University)
Die Wirkung von Acamprosat auf die Hinweisreizreaktivität abstinenter Alkoholabhängiger
Jahnke, K. (2008) · FreiDok plus (Universitätsbibliothek Freiburg)
Pharmacologie du baclofène et applications cliniques en addictologie
Imbert, B. (2016) · theses.fr (ABES) · doi:10.70675/96dc9dcezae81z437ezb562z6e498be66a8f
A multi-reward framework to improve translation in alcohol use disorder
Guerrin, C. G. J., & Ahmed, S. H. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113373
Elucidating the role of alpha1-containing GABA(A) receptors in ethanol action
Werner, D. F. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
Studies of acamprosate for the treatment of alcohol dependence
Hammarberg, A. (2009) · Figshare
Metadata
- Authors
- Cole, J. C., Littleton, J. M., & Little, H. J.
- Affiliations
- Durham University (GB)
- University of Kentucky (US)
- Venue
- Psychopharmacology
- Published
- 2000-01-10
- Volume
- 147
- Issue
- 4
- Pages
- 403-411
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1993776646
- Cited by
- 65
- References
- 18
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 1 · 2012: 6
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- acamprosate, naltrexone, alcohol relapse, negative reinforcement, positive reinforcement, elevated plus maze, alcoholism treatment, alcohol expectancies
- MeSH terms
- Acamprosate, Alcohol Deterrents, Ethanol, Animals, Anxiety, Central Nervous System Depressants, Exploratory Behavior, Male, Naltrexone, Substance Withdrawal Syndrome, Taurine, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.